Yacoub Sinda, Ons Gharbi, Khemiss Mehdi
Department of Dental Medicine, Sahloul University Hospital, Sousse, Tunisia.
Faculty of Dental Medicine, University of Monastir, Tunisia.
Dent Med Probl. 2025 Jan-Feb;62(1):145-160. doi: 10.17219/dmp/186553.
Botulinum toxin type A (BTX-A) injections have emerged as a promising alternative for the management of bruxism. In this context, a systematic review of randomized controlled trials on the impact of BTX-A on patients with bruxism was conducted. A literature search of multiple online electronic databases (PubMed®, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL)) was undertaken from their inception to February 1, 2024. The Medical Subject Headings (MeSH) included "Botulinum Toxins", "Botulinum Toxins, Type A", "Bruxism", and "Sleep Bruxism", which were combined with the Boolean operators "AND" and "OR". The methodological quality of each included study was assessed using the Joanna Briggs Institute (JBI) critical appraisal tool. Reducing muscle pain and activity were assessed as primary outcomes, while the quality of sleep was considered as a secondary outcome. Twelve articles met the inclusion criteria. The risk of bias was low in 10 studies and moderate in 2. Bilateral injections of BTX-A into the masseter, temporalis and medial pterygoid muscles were compared to saline injections, the use of occlusal splints and conventional treatment. Of the 12 studies, 6 reported a reduction in muscle activity recorded by rhythmic masticatory muscle activity (RMMA) and electromyography (EMG) after the administration of BTX-A. In addition, 3 studies indicated that the intensity of muscle pain, measured using the visual analogue scale (VAS), decreased significantly in individuals with bruxism who received BTX-A. Finally, 1 study highlighted improved sleep quality in patients with bruxism who were rehabilitated with a single-arch implant overdenture and received either BTX-A or occlusal appliances. Botulinum toxin type A can effectively reduce symptoms of bruxism. However, the included studies exhibited heterogeneity and methodological differences. Long-term follow-up studies with large sample sizes and the incorporation of repeated injections are necessary to further validate the findings.
A型肉毒毒素(BTX-A)注射已成为治疗磨牙症的一种有前景的替代方法。在此背景下,对关于BTX-A对磨牙症患者影响的随机对照试验进行了系统评价。对多个在线电子数据库(PubMed®、Scopus、科学网和Cochrane对照试验中央注册库(CENTRAL))从建库至2024年2月1日进行了文献检索。医学主题词(MeSH)包括“肉毒毒素”、“A型肉毒毒素”、“磨牙症”和“睡眠磨牙症”,并与布尔运算符“AND”和“OR”组合使用。使用乔安娜·布里格斯研究所(JBI)批判性评价工具评估每项纳入研究的方法学质量。将减轻肌肉疼痛和活动作为主要结局,而将睡眠质量视为次要结局。12篇文章符合纳入标准。10项研究的偏倚风险较低,2项研究的偏倚风险为中等。将双侧咬肌、颞肌和翼内肌注射BTX-A与注射生理盐水、使用咬合板和传统治疗进行了比较。在这12项研究中,6项报告称,注射BTX-A后,通过节律性咀嚼肌活动(RMMA)和肌电图(EMG)记录的肌肉活动有所减少。此外,3项研究表明,使用视觉模拟量表(VAS)测量,接受BTX-A的磨牙症患者的肌肉疼痛强度显著降低。最后,1项研究强调,接受单牙弓种植覆盖义齿修复并接受BTX-A或咬合器具治疗的磨牙症患者的睡眠质量有所改善。A型肉毒毒素可有效减轻磨牙症症状。然而,纳入的研究存在异质性和方法学差异。需要进行大样本量的长期随访研究并纳入重复注射,以进一步验证研究结果。